CERTIFICATE OF ANALYSIS

PuriLab Analytical

Tirzepatide + Retatrutide 60 mg

TR-2026-001 Lot NOT PROVIDED Analyzed November 3, 2026



TIMELINE

ORDERED
October 28, 2026

RECEIVED
November 2, 2026

ANALYZED
November 3, 2026

SAMPLE

NAME
Tirzepatide + Retatrutide 60 mg

EXPECTED
Tirzepatide + Retatrutide

AMOUNT
1 vial, lyophilized powder

TESTING

CLIENT
4Ever Research

TEST TYPE
Content & purity

METHOD
HPLC-UV

CONTENT, HOW MUCH IS IN IT

Tirzepatide	**37.28** mg	Label claim: 40 mg
Retatrutide	**25.15** mg	Label claim: 20 mg


PURITY, HOW CLEAN IT IS

99.5%

by HPLC-UV peak area, system peaks excluded

CHROMATOGRAM

HPLC-UV



● 18.06 min, Retatrutide ● 18.81 min, Tirzepatide

ANALYST COMMENTS

White lyophilized powder, clear-cap vial, received sealed.

ANALYST SIGNATURE

Max Barrett
Lab Director, PuriLab Analytical
Analysis date: November 3, 2026

VERIFICATION CODE

TR-7FI7-CZ6K

Verify at purilab.org/verify/TR-7FI7-CZ6K

SCAN TO VERIFY

TR-7FI7-CZ6K

Results apply solely to the sample as received and are not representative of any larger lot, batch, or production run. Findings are limited to the analytes stated above. PuriLab Analytical is an independent testing laboratory, is not CLIA certified or ISO 17025 accredited, does not sell or distribute any substance, and makes no representation as to the safety, legality, or fitness of any material for any use.